Literature DB >> 15226377

CD133, a novel marker for human prostatic epithelial stem cells.

Gavin D Richardson1, Craig N Robson, Shona H Lang, David E Neal, Norman J Maitland, Anne T Collins.   

Abstract

Stem cells are clonogenic cells with self-renewal and differentiation properties, which may represent a major target for genetic damage leading to prostate cancer and benign prostatic hyperplasia. Stem cells remain poorly characterised because of the absence of specific molecular markers that permit us to distinguish them from their progeny, the transit amplifying cells, which have a more restricted proliferative potential. Human CD133 antigen, also known as AC133, was recently identified as a haematopoietic stem cell marker. Here we show that a small population (approximately 1%) of human prostate basal cells express the cell surface marker CD133 and are restricted to the alpha(2)beta(1)(hi) population, previously shown to be a marker of stem cells in prostate epithelia. alpha(2)beta(1)(hi)/CD133(+) cells exhibit two important attributes of epithelial stem cells: they possess a high in vitro proliferative potential and can reconstitute prostatic-like acini in immunocompromised male nude mice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15226377     DOI: 10.1242/jcs.01222

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  269 in total

Review 1.  Prostate cancer stem cell biology.

Authors:  C Yu; Z Yao; Y Jiang; E T Keller
Journal:  Minerva Urol Nefrol       Date:  2012-03       Impact factor: 3.720

2.  Selective inhibitory effect of HPMA copolymer-cyclopamine conjugate on prostate cancer stem cells.

Authors:  Yan Zhou; Jiyuan Yang; Jindřich Kopeček
Journal:  Biomaterials       Date:  2011-12-03       Impact factor: 12.479

3.  CD133+ CD44+ subgroups may be human small intestinal stem cells.

Authors:  Neng-Yi Hou; Kun Yang; Tie Chen; Xin-Zu Chen; Bo Zhang; Xian-Ming Mo; Jian-Kun Hu
Journal:  Mol Biol Rep       Date:  2010-06-06       Impact factor: 2.316

Review 4.  The androgen receptor and stem cell pathways in prostate and bladder cancers (review).

Authors:  Katarzyna Marcinkiewicz; Kymora B Scotland; Stephen A Boorjian; Emeli M Nilsson; Jenny Liao Persson; Per Anders Abrahamsson; Cinzia Allegrucci; Ieuan A Hughes; Lorraine J Gudas; Nigel P Mongan
Journal:  Int J Oncol       Date:  2011-09-28       Impact factor: 5.650

5.  Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells.

Authors:  Murielle Mimeault; Sonny L Johansson; Jean-Pierre Henichart; Patrick Depreux; Surinder K Batra
Journal:  Mol Cancer Ther       Date:  2010-02-23       Impact factor: 6.261

6.  Single-nucleotide polymorphisms of stemness genes predicted to regulate RNA splicing, microRNA and oncogenic signaling are associated with prostate cancer survival.

Authors:  Jennifer A Freedman; Yanru Wang; Xuechan Li; Hongliang Liu; Patricia G Moorman; Daniel J George; Norman H Lee; Terry Hyslop; Qingyi Wei; Steven R Patierno
Journal:  Carcinogenesis       Date:  2018-07-03       Impact factor: 4.944

Review 7.  CD133: to be or not to be, is this the real question?

Authors:  Elena Irollo; Giuseppe Pirozzi
Journal:  Am J Transl Res       Date:  2013-09-25       Impact factor: 4.060

Review 8.  Cancer stem cells in lung cancer: Evidence and controversies.

Authors:  Muhammad Alamgeer; Craig D Peacock; William Matsui; Vinod Ganju; D Neil Watkins
Journal:  Respirology       Date:  2013-07       Impact factor: 6.424

9.  Dysplasia of human prostate CD133(hi) sub-population in NOD-SCIDS is blocked by c-myc anti-sense.

Authors:  S M Goodyear; M D Amatangelo; M E Stearns
Journal:  Prostate       Date:  2009-05-15       Impact factor: 4.104

Review 10.  Exploring the origins of the normal prostate and prostate cancer stem cell.

Authors:  Susan Kasper
Journal:  Stem Cell Rev       Date:  2008-09       Impact factor: 5.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.